{
    "body": "Pridopidine has been tested for treatment of which disorder?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23446684", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21586914", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20616707", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22948856", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22071279", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20667452", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22560595", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23450660", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23468085", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20373247"
    ], 
    "ideal_answer": [
        "Pridopidine is a dopaminergic stabilizer that has shown promising results for treatment of Huntington disease patients."
    ], 
    "exact_answer": [
        "Huntington disease"
    ], 
    "type": "factoid", 
    "id": "550ea8f1b305b40c5c000005", 
    "snippets": [
        {
            "offsetInBeginSection": 1892, 
            "offsetInEndSection": 2083, 
            "text": "These effects of pridopidine may serve to strengthen the cortico-striatal communication and to improve motor control in Huntington's disease for which pridopidine is currently in development.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23468085", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 92, 
            "text": "A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23450660", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 207, 
            "text": "We examined the effects of 3 dosages of pridopidine, a dopamine-stabilizing compound, on motor function and other features of Huntington's disease, with additional evaluation of its safety and tolerability. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23450660", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1304, 
            "offsetInEndSection": 1497, 
            "text": "Although the primary analysis did not demonstrate a statistically significant treatment effect, the overall results suggest that pridopidine may improve motor function in Huntington's disease. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23450660", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 92, 
            "text": "One-year safety and tolerability profile of pridopidine in patients with Huntington disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446684", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 126, 
            "text": "OBJECTIVE: To assess the 1-year safety profile of the dopaminergic stabilizer pridopidine in patients with Huntington disease.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446684", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1430, 
            "offsetInEndSection": 1616, 
            "text": "CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that pridopidine (\u226490 mg/day) is generally safe and well-tolerated in patients with Huntington disease for up to 1 year.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446684", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 211, 
            "text": "Pridopidine is being developed for the treatment of impaired motor function associated with Huntington's disease and belongs to a new class of compounds known as dopidines, which act as dopaminergic stabilizers.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22948856", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 248, 
            "offsetInEndSection": 431, 
            "text": " There is so far neither cure nor approved disease-slowing therapy for HD, though recent clinical studies have shown a beneficial long-term effect of pridopidine in patients with HD. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560595", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 160, 
            "text": "Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22071279", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 139, 
            "offsetInEndSection": 652, 
            "text": "Pridopidine belongs to a new class of compounds known as dopaminergic stabilisers, and results from a small phase 2 study in patients with Huntington's disease suggested that this drug might improve voluntary motor function. We aimed to assess further the effects of pridopidine in patients with Huntington's disease. METHODS: We undertook a 6 month, randomised, double-blind, placebo-controlled trial to assess the efficacy of pridopidine in the treatment of motor deficits in patients with Huntington's disease.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22071279", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2432, 
            "offsetInEndSection": 2725, 
            "text": "INTERPRETATION: This study did not provide evidence of efficacy as measured by the mMS, but a potential effect of pridopidine on the motor phenotype of Huntington's disease merits further investigation. Pridopidine up to 90 mg per day was well tolerated in patients with Huntington's disease. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22071279", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 109, 
            "text": "Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21586914", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 221, 
            "offsetInEndSection": 748, 
            "text": "Pridopidine (ACR16) belongs to a novel class of central nervous system compounds in development for the treatment of Huntington disease. The objective of the study was to investigate the metabolic changes in patients with Huntington disease before and after pridopidine treatment. METHODS: [(18)F]Fluorodeoxyglucose positron emission tomographic imaging was used to measure the regional cerebral metabolic rate of glucose at baseline and after 14 days of open-label pridopidine treatment in 8 patients with Huntington disease. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21586914", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1163, 
            "offsetInEndSection": 1562, 
            "text": "CONCLUSIONS: Our findings suggest that pridopidine induces metabolic changes in brain regions implicated as important for mediating compensatory mechanisms in Huntington disease. In addition, the finding of a strong relationship between clinical severity and metabolic activity after treatment also suggests that pridopidine treatment targets a Huntington disease-related metabolic activity pattern.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21586914", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1365, 
            "offsetInEndSection": 1574, 
            "text": "The putative restoration of function in cortico-subcortical circuitry by pridopidine is likely to make it useful for ameliorating several neurological and psychiatric disorders, including Huntington's disease.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20667452", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 109, 
            "text": "Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616707", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 294, 
            "text": "OBJECTIVES: To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease (HD). METHODS: In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616707", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1151, 
            "offsetInEndSection": 1237, 
            "text": "CONCLUSIONS: Pridopidine shows promise as a treatment for some of the symptoms of HD. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616707", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 647, 
            "offsetInEndSection": 841, 
            "text": "Investigational drugs discussed include ALN-HTT (Alnylam Pharmaceuticals Inc/Medtronic Inc), EPI-743 (Edison Pharmaceuticals Inc), LNK-754 (Link Medicine Corp) and pridopidine (NeuroSearch A/S).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20373247", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1869, 
            "offsetInEndSection": 2061, 
            "text": "These effects of pridopidine may serve to strengthen the cortico-striatal communication and to improve motor control in Huntington's disease for which pridopidine is currently in development.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23468085", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1287, 
            "offsetInEndSection": 1508, 
            "text": "In addition, the finding of a strong relationship between clinical severity and metabolic activity after treatment also suggests that pridopidine treatment targets a Huntington disease-related metabolic activity pattern.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21586914", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1109, 
            "offsetInEndSection": 1181, 
            "text": "Pridopidine shows promise as a treatment for some of the symptoms of HD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616707", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 72, 
            "text": "Pridopidine shows promise as a treatment for some of the symptoms of HD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616707", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 166, 
            "offsetInEndSection": 386, 
            "text": "In addition, the finding of a strong relationship between clinical severity and metabolic activity after treatment also suggests that pridopidine treatment targets a Huntington disease-related metabolic activity pattern.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21586914", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 204, 
            "text": "We examined the effects of 3 dosages of pridopidine, a dopamine-stabilizing compound, on motor function and other features of Huntington's disease, with additional evaluation of its safety and tolerability", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23450660", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1891, 
            "offsetInEndSection": 2081, 
            "text": "These effects of pridopidine may serve to strengthen the cortico-striatal communication and to improve motor control in Huntington's disease for which pridopidine is currently in development", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23468085", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1302, 
            "offsetInEndSection": 1522, 
            "text": "In addition, the finding of a strong relationship between clinical severity and metabolic activity after treatment also suggests that pridopidine treatment targets a Huntington disease-related metabolic activity pattern.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21586914", 
            "endSection": "abstract"
        }
    ]
}